Variables significant at the 10% level in the multiple regression models together with adjusted coefficients, SEs and significance levels
| Domain | Coefficient (SE) | p Value | Domain | Coefficient (SE) | p Value |
|---|---|---|---|---|---|
| Physical functioning | Social functioning | ||||
| Age (5 years increase) | −0.10 (0.03) | <0.001 | Age (5 years increase) | −0.11 (0.04) | 0.008 |
| BMI (1 unit decrease) | −0.10 (0.04) | 0.007 | CFRD | −0.28 (0.11) | 0.015 |
| TIVAD | −0.34 (0.08) | <0.001 | BMI (1 unit decrease) | −0.07 (0.04) | 0.078 |
| Burkholderia cepacia complex | −0.36 (0.18) | 0.053 | B. cepacia complex | −0.65 (0.25) | 0.008 |
| FEV1% (10% decrease) | −0.20 (0.04) | <0.001 | FEV1% (10% decrease) | −0.13 (0.05) | 0.004 |
| Listed for transplant | −0.37 (0.11) | <0.001 | Listed for transplant | −0.45 (0.15) | 0.004 |
| Received transplant | −0.73 (0.27) | 0.007 | |||
| Emotional responses | Treatment issues | ||||
| Age (5 years increase) | −0.19 (0.03) | <0.001 | Age (5 years increase) | −0.18 (0.03) | <0.001 |
| CFRD | −0.16 (0.08) | 0.032 | BMI (1 unit decrease) | −0.09 (0.02) | <0.001 |
| TIVAD | −0.13 (0.07) | 0.087 | Oral supplements | −0.19 (0.10) | 0.068 |
| FEV1% (10% decrease) | −0.11 (0.03) | <0.001 | TIVAD | −0.36 (0.09) | <0.001 |
| Listed for transplant | −0.35 (0.11) | 0.002 | B. cepacia complex | −0.39 (0.20) | 0.045 |
| FEV1% (10% decrease) | −0.06 (0.03) | 0.078 | |||
| Listed for transplant | −0.35 (0.15) | 0.019 | |||
| Received transplant | 0.67 (0.21) | 0.001 | |||
| Chest symptoms | Body image | ||||
| Age (5 years increase) | −0.07 (0.03) | 0.054 | Female | 0.58 (0.13) | <0.001 |
| CFRD | −0.21 (0.10) | 0.027 | CFRD | −0.22 (0.09) | 0.013 |
| BMI (1 unit decrease) | −0.10 (0.03) | 0.001 | BMI (1 unit decrease) | −0.15 (0.02) | <0.001 |
| TIVAD | −0.35 (0.09) | <0.001 | Enteral tube feeds | −0.24 (0.13) | 0.069 |
| B. cepacia complex | −0.48 (0.19) | 0.013 | TIVAD | −0.30 (0.09) | 0.001 |
| FEV1% (10% decrease) | 0.17 (0.03) | <0.001 | B. cepacia complex | −0.57 (0.18) | 0.002 |
| Listed for transplant | −0.41 (0.13) | 0.002 | Received transplant | −0.39 (0.17) | 0.022 |
| Received transplant | 0.79 (0.21) | <0.001 | |||
| Interpersonal relationships | Career concerns | ||||
| Age (5 years increase) | −0.08 (0.02) | <0.001 | Age (5 years increase) | −0.15 (0.03) | <0.001 |
| CFRD | −0.11 (0.06) | 0.081 | TIVAD | −0.46 (0.08) | <0.001 |
| Oral supplements | 0.11 (0.06) | 0.081 | FEV1% (10% decrease) | −0.16 (0.03) | <0.001 |
| TIVAD | −0.16 (0.06) | 0.011 | Listed for transplant | −0.31 (0.14) | 0.019 |
| FEV1% (10% decrease) | −0.10 (0.03) | 0.001 | Received transplant | −0.71 (0.19) | <0.001 |
| Concerns for the future | |||||
| Age (5 years increase) | −0.19 (0.03) | <0.001 | |||
| Female | −0.26 (0.13) | 0.057 | |||
| BMI (1 unit decrease) | −0.06 (0.02) | 0.010 | |||
| TIVAD | −0.22 (0.07) | 0.001 | |||
| Listed for transplant | −0.37 (0.12) | 0.002 | |||
| Received transplant | 0.41 (0.17) | 0.015 | |||
BMI, body mass index; CFRD, cystic fibrosis-related diabetes; FEV1, forced expiratory volume in 1 s, TIVAD, totally implantable vascular access device.